📰 Practice Guidelines News
Page 27 - Practice Guidelines News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Practice Guidelines. Real-time updates on events, politics, business and more.
April 6, 2023
Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.
April 4, 2023
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the addition of the University of Chicago Medicine Comprehensive Cancer...
April 4, 2023
University of Chicago Medicine Comprehensive Cancer Center has joined the National Comprehensive Cancer Network as its 33rd member institution.The alliance of top U.S. academic cancer centers — started by 13 founding member institutions in 1995 — aims to improve and enable high-quality, effective and accessible care for patients with cancer.
April 4, 2023
New research in the April 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that specially trained oncology infusion room nurses can improve advance care planning (ACP) for patients with advanced cancer. As compared to patients who received standard care, those who participated in targeted and specialized intervention had a dramatically increased rate of creating advance directives and taking part in conversation about end-of-life issues.
March 30, 2023
Operator: Good day and thank you for standing by. Welcome to the Aadi Bioscience Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
March 28, 2023
Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
March 27, 2023
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the...
March 23, 2023
Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.
March 20, 2023
Anthelmintic resistance represents a huge threat to equine health and welfare: “If horse owners don’t make these changes now, it will be too late,” says BEVA boss David Rendle.
March 17, 2023
A review of new approvals and guideline changes for use of T-DXd in second- and third-line treatment of HER2-positive and HER2-low breast cancer.